[go: up one dir, main page]

WO2001026641A3 - Methode destinee au traitement de l'obesite - Google Patents

Methode destinee au traitement de l'obesite Download PDF

Info

Publication number
WO2001026641A3
WO2001026641A3 PCT/US2000/027252 US0027252W WO0126641A3 WO 2001026641 A3 WO2001026641 A3 WO 2001026641A3 US 0027252 W US0027252 W US 0027252W WO 0126641 A3 WO0126641 A3 WO 0126641A3
Authority
WO
WIPO (PCT)
Prior art keywords
obesity
treatment
morpholinol
derivatives
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/027252
Other languages
English (en)
Other versions
WO2001026641A2 (fr
Inventor
Jessica E Matthews
David Lee Musso
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9924275.2A external-priority patent/GB9924275D0/en
Priority claimed from GB0001861A external-priority patent/GB0001861D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to AU77501/00A priority Critical patent/AU7750100A/en
Priority to JP2001529431A priority patent/JP2003511410A/ja
Priority to EP00967281A priority patent/EP1220673A2/fr
Publication of WO2001026641A2 publication Critical patent/WO2001026641A2/fr
Publication of WO2001026641A3 publication Critical patent/WO2001026641A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une méthode destinée au traitement de l'obésité, consistant à administrer à un animal nécessitant ce traitement, un composé représenté par la formule générale (I), ou un sel pharmaceutiquement acceptable de celui-ci ou un solvate pharmaceutiquement acceptable de celui-ci. L'invention concerne également des méthodes destinées à supprimer l'appétit, entraînant une perte de poids, prévenant la prise de poids, affectant de préférence les compositions adipeuses, inhibant l'état de manque de nourriture et permettant de maintenir la perte de poids.
PCT/US2000/027252 1999-10-13 2000-10-03 Methode destinee au traitement de l'obesite Ceased WO2001026641A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU77501/00A AU7750100A (en) 1999-10-13 2000-10-03 Method for the treatment of obesity
JP2001529431A JP2003511410A (ja) 1999-10-13 2000-10-03 肥満症の治療のためのモルホリノール誘導体
EP00967281A EP1220673A2 (fr) 1999-10-13 2000-10-03 Methode destinee au traitement de l'obesite

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9924275.2A GB9924275D0 (en) 1999-10-13 1999-10-13 Method for the treatment of obesity
GB9924275.2 1999-10-13
GB0001861A GB0001861D0 (en) 2000-01-28 2000-01-28 Method for the treatment of obesity
GB0001861.4 2000-01-28

Publications (2)

Publication Number Publication Date
WO2001026641A2 WO2001026641A2 (fr) 2001-04-19
WO2001026641A3 true WO2001026641A3 (fr) 2002-01-10

Family

ID=26243494

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/027252 Ceased WO2001026641A2 (fr) 1999-10-13 2000-10-03 Methode destinee au traitement de l'obesite

Country Status (6)

Country Link
EP (1) EP1220673A2 (fr)
JP (1) JP2003511410A (fr)
AR (1) AR026022A1 (fr)
AU (1) AU7750100A (fr)
PE (1) PE20010744A1 (fr)
WO (1) WO2001026641A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US9125868B2 (en) 2006-11-09 2015-09-08 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
US9248123B2 (en) 2010-01-11 2016-02-02 Orexigen Therapeutics, Inc. Methods of providing weight loss therapy in patients with major depression
US9457005B2 (en) 2005-11-22 2016-10-04 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005508675A (ja) 2001-08-08 2005-04-07 ケヴィン アール． オートン， 電気導電的な体重減少のための装置および方法
EP2301537A1 (fr) * 2002-05-17 2011-03-30 Duke University Zonisamide pour le traitement de l'obésité
MXPA05011557A (es) 2003-04-29 2006-03-09 Orexigen Therapeutics Inc Composiciones para afectar perdida de peso.
WO2009071678A2 (fr) * 2007-12-05 2009-06-11 Biovitrum Ab (Publ) Nouveaux composés iv
MX2010012909A (es) 2008-05-30 2011-02-25 Orexigen Therapeutics Inc Metodos para tratamiento de condiciones de grasa visceral.
MX2010013353A (es) * 2008-06-04 2010-12-21 Astrazeneca Ab Nuevos compuestos vii.
KR20200035501A (ko) 2012-06-06 2020-04-03 오렉시젠 세러퓨틱스 인크. 과체중 및 비만의 치료 방법

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0426416A1 (fr) * 1989-10-31 1991-05-08 The Wellcome Foundation Limited Nouveaux composés de morpholinole, leur préparation et leur application
WO1998047513A1 (fr) * 1997-04-24 1998-10-29 Merck Sharp & Dohme Limited Utilisation des antagonistes du recepteur de nk-1 dans le traitement des troubles alimentaires
WO1999025355A1 (fr) * 1997-11-14 1999-05-27 Glaxo Group Ltd. Procede de traitement de l'accoutumance a des produits contenant de la nicotine
WO1999037305A1 (fr) * 1998-01-21 1999-07-29 Glaxo Group Limited Morpholinol pharmaceutiquement actif
WO2000018406A1 (fr) * 1998-09-28 2000-04-06 Glaxo Group Limited Formes posologiques a administration par voie orale contenant le compose (2s,3s,5r)-2-(3,5-difluorophenyl)-3,5-dimethyl-2-morpholinol et une quantite stabilisante efficace d'acide alginique

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0426416A1 (fr) * 1989-10-31 1991-05-08 The Wellcome Foundation Limited Nouveaux composés de morpholinole, leur préparation et leur application
WO1998047513A1 (fr) * 1997-04-24 1998-10-29 Merck Sharp & Dohme Limited Utilisation des antagonistes du recepteur de nk-1 dans le traitement des troubles alimentaires
WO1999025355A1 (fr) * 1997-11-14 1999-05-27 Glaxo Group Ltd. Procede de traitement de l'accoutumance a des produits contenant de la nicotine
WO1999037305A1 (fr) * 1998-01-21 1999-07-29 Glaxo Group Limited Morpholinol pharmaceutiquement actif
WO2000018406A1 (fr) * 1998-09-28 2000-04-06 Glaxo Group Limited Formes posologiques a administration par voie orale contenant le compose (2s,3s,5r)-2-(3,5-difluorophenyl)-3,5-dimethyl-2-morpholinol et une quantite stabilisante efficace d'acide alginique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KELLEY JAMES L ET AL: "-2-(3,5-difluorophenyl)-3,5-dimethyl-2-morpholinol: A novel antidepressant agent and selective inhibitor of norepinephrine uptake.", JOURNAL OF MEDICINAL CHEMISTRY, vol. 39, no. 2, 1996, pages 347 - 349, XP002164358, ISSN: 0022-2623 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9457005B2 (en) 2005-11-22 2016-10-04 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US9107837B2 (en) 2006-06-05 2015-08-18 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US9125868B2 (en) 2006-11-09 2015-09-08 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
US9248123B2 (en) 2010-01-11 2016-02-02 Orexigen Therapeutics, Inc. Methods of providing weight loss therapy in patients with major depression

Also Published As

Publication number Publication date
AU7750100A (en) 2001-04-23
PE20010744A1 (es) 2001-07-23
JP2003511410A (ja) 2003-03-25
WO2001026641A2 (fr) 2001-04-19
EP1220673A2 (fr) 2002-07-10
AR026022A1 (es) 2002-12-26

Similar Documents

Publication Publication Date Title
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
WO2001026641A3 (fr) Methode destinee au traitement de l'obesite
HK1040703A1 (zh) 作為血管破壞劑的秋水仙醇類衍生物
CA2455774A1 (fr) Derives de sucre d'hydromorphone, dihydromorphine et dihydroisomorphine, leurs compositions et leur utilisation dans le traitement ou la prevention de la douleur
WO2004029031A3 (fr) Agents therapeutiques utiles dans le traitement de la douleur
TR200102646T2 (tr) Yeme bozukluklarının tedavi edilmesi.
WO2004012700A3 (fr) Nouvelle forme galenique
HK1038564A1 (zh) 用作糖原合酶激酶-3抑制劑的吡咯-2，5-二酮
MXPA05006940A (es) Formulaciones terapeuticas para el tratamiento de enfermedades relacionadas con beta - amiloide.
EP0787497A3 (fr) Préparation pharmaceutique contenant l'hormone de croissance humaine
AU2002239830A1 (en) Pyruvate cardioplegia solutions for administration to the heart during cardiopulmonary surgery and methods of use thereof
WO2000068198A3 (fr) Derives de pyridine heterosubstitues utilises comme inhibiteurs de pde 4
EP4574822A3 (fr) Composés et compositions pour leur utilisation dans le traitement de troubles cutanés
NZ332965A (en) 4- or 7-benzylamino or benzylmethyl substituted 2-methyl-benzimidazole derivatives
WO2000064874A3 (fr) DERIVES DE PYRIDINE HETEROSUBSTITUES INHIBITEURS DE $i(PDE 4)
EP1166778A3 (fr) Utilisation d'un sécrétagogue d'hormone de croissance pour traiter le lupus érythémateux systémique et les maladies intestinales inflammatoires
CA2389032A1 (fr) Agents de prevention ou de traitement de maladies inflammatoires de l'intestin
WO2001030331A3 (fr) Compositions therapeutiques comprenant des inhibiteurs de la proteine kinase c
WO1998006265A3 (fr) Traitement d'infections fongiques a l'aide d'une combinaison d'un compose antifongique et d'un compose n-alkyle heterocyclique
KR950016741A (ko) 체중 증가를 억제하거나 또는 체중 감소를 유도하는 방법
HU9203849D0 (en) Thiazole derivatives
EP1209166A4 (fr) Nouveaux derives a-500359
ZA200105886B (en) Agent of treating Parkinson's disease comprising astrocyte function-improving agent as active ingredient.
CA2443235A1 (fr) Compositions pharmaceutiques comprenant de l'ascomycine
AU2001243369A1 (en) Composition and method to treat weight gain and obesity attributable to psychotropic drugs

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000967281

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 529431

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 10110624

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000967281

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000967281

Country of ref document: EP